Early discontinuation of immune checkpoint inhibitors after objective response in real-world melanoma: Clinical and economic impact

This publication has 30 references indexed in Scilit:

• When to stop immunotherapy for advanced melanoma: the emulated target trials
  eClinicalMedicine, 2024
• Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study
  Annals of Oncology, 2024
• Anti-PD-1: When to Stop Treatment
  Current Oncology Reports, 2022
• Clinical value of routine [18F]2‐fluoro‐2‐deoxy‐d‐glucose positron emission tomography scans as a decision tool for early immunotherapy discontinuation in advanced melanoma
  International Journal of Cancer, 2022
• Immune checkpoint inhibitors in melanoma
  The Lancet, 2021
• The Danish metastatic melanoma database (DAMMED): A nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients
  Cancer Epidemiology, 2021
• Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy
  European Journal of Cancer, 2021
• Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response
  European Journal of Cancer, 2021
• ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
  Annals of Oncology, 2020
• Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
  The Lancet Oncology, 2018